BPC-157 is one of the most studied peptides in animal models of injury. The question is what a rat result can, and cannot, say about people.
BPC-157 · Gastric-derived pentadecapeptide
When tissue is damaged, the body has to rebuild blood supply, recruit repair cells and lay down new fibres in the right order. Researchers use animal injury models to test whether a molecule changes that sequence. BPC-157 is studied because, in rats, it has repeatedly altered the course of healing in tendon, muscle and gut. Human data are limited to a few small pilot studies.
BPC-157 is a synthetic pentadecapeptide, fifteen amino acids, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a partial sequence of 'body protection compound', a protein its developers reported in human gastric juice. That larger protein has been characterised mainly by the Zagreb group that introduced the peptide, and the gastric origin should be read as their account rather than an independently established fact. The peptide itself is a laboratory construct that is stable in gastric acid, which is why it was first studied in the stomach and gut.
No single receptor has been confirmed. Mechanisms proposed from animal and cell work include effects on blood-vessel growth, on nitric oxide signalling, and on the movement and survival of fibroblasts, the cells that produce collagen. A 2025 narrative review by McGuire and colleagues summarises these pathways and notes that human data remain extremely limited.
The best-known experiments use rats with a surgically cut Achilles tendon. Staresinic and colleagues (2003) gave BPC-157 by intraperitoneal injection daily from 30 minutes after surgery and measured load to failure, a functional walking index and tissue structure over 14 days, reporting improvement on each measure compared with saline. Chang and colleagues (2011), an independent group in Taiwan, studied rat tendon cells in culture and found that BPC-157 increased their outgrowth, migration and survival under oxidative stress, through a signalling pathway involved in cell attachment, without increasing their proliferation.
The wider rodent literature, much of it from Sikiric and colleagues in Zagreb, covers gastric and intestinal lesions, muscle crush injury, blood-vessel occlusion and other models. Two features shape how it should be read: most studies come from one affiliated group, and injury, route and timing were chosen by the experimenters.
Human evidence is thin. The 2025 review identified three small pilot studies in people, covering knee pain, interstitial cystitis and intravenous safety, none large or controlled enough to establish efficacy. The knee-pain report was a retrospective chart review from one US clinic: 16 patients reached by telephone six to twelve months after intra-articular injection, four of whom had received BPC-157 together with thymosin β4, with self-reported pain relief and no control group (Lee and Padgett, 2021). BPC-157 is not an approved medicine in any jurisdiction.
A cut rat tendon treated within half an hour of surgery, under controlled conditions, is not the same as a human injury of unknown age, and results in the first do not transfer to the second. The receptor or receptors involved are not identified, so it is not possible to predict effects across tissues. Dose, route and timing in the animal work vary widely, and no human trial has defined any of them. Long-term safety in people, including the consequences of promoting blood-vessel growth, has not been studied. The concentration of the literature in one group means independent replication is limited, though it does exist for some cell-level findings.
In Australia BPC-157 is a Schedule 4 (prescription only) substance under the Poisons Standard, and listed in Appendix D (clause 5), which the states and territories apply through their own poisons legislation to restrict possession without authority; the entries took effect on 1 June 2024 and remain in the June 2026 instrument. It is not an approved medicine in Australia, and no approval elsewhere was identified. BPC-157 is named under S0 (non-approved substances) on the WADA 2026 Prohibited List, prohibited at all times.
Sources and status checked 2026-09-23
BPC-157 — sizes and pricing